HSINCHU, TAIWAN – October 2, 2015—JHL Biotech (TWEM: 6540), an emerging biosimilars company incorporated in Cayman Islands and based in Taiwan and China, announced today it has been publicly listed on the Taiwan Emerging Stock Board, effective September 17, 2015.
JHL Biotech’s current capital value is $1.89 billion in New Taiwan dollars. The Taiwan Emerging Stock Board (ESB) is an introductory listing for companies before listing on Taipei Exchange (TPEx) or the Taiwan Stock Exchange (TWSE).
JHL Biotech’s public offering is made by certain shareholders selling a portion of their current holdings of JHL Biotech’s common stock. Yuanta Securities is the lead underwriter. Investors can contact JHL Biotech or buy directly from the Taiwan Emerging Stock Board.
About JHL Biotech
JHL Biotech is an emerging biopharmaceuticals company founded by a group of biotech veterans with decades of manufacturing experience. JHL Biotech has been backed by a consortium of top-tier venture capital firms including Kleiner Perkins Caufield & Byers, Sequoia Capital, Biomark Capital and China Development Industrial Bank (CDIB). JHL Biotech’s mission is to provide affordable world-class medicines to more patients worldwide. JHL Biotech concentrates on developing new protein drugs and biosimilars that comply with international standards. JHL Biotech has capability on cell line development, cell culture, purification, formulation, stability test and GMP manufacturing. In addition to in-house research and development, JHL Biotech has signed co-development agreements with four international medical companies.
A key component for JHL in achieving its vision is its state-of-the-art facilities that are built in compliance with United States, European Union and International Conference on Harmonisation (ICH) current good manufacturing practices (cGMP) regulations and guidelines. The company has facilities in Taiwan that support all pre-clinical and early clinical activities for biologics development. JHL is currently building facilities to support commercial manufacturing in Wuhan, China, with an expected completion within two years. With this comprehensive infrastructure in place, JHL Biotech is uniquely positioned to deliver manufacturing solutions to its worldwide partners. For more information about the company, visit www.jhlbiotech.com.
Racho Jordanov and Rose Lin, Founders Phone: +886-(0)3-658-3899
This release contains forward-looking statements (the “Statements”) regarding future events and the future performance of JHL Biotech Inc. (the “Company”). The readers, viewers and recipients of the Statements are advised to acknowledge and understand that there are risks and uncertainties that could cause the actual results of the Company to significantly differ from the Statements. The Statements are based on the management’s current understanding and expectations. The Statements include but are not limited to information that relate to the business, goals, strategy, drug candidates, safety and efficacy of the drug products, product approvals, market potential, product sales, revenue, development, regulatory and approval timelines, product launches, product acquisitions, capital resources and any statements that relate to the intent, belief, forecasts, plans or expectations of the Company or its management, or that are not a statement of historical fact.
Risks that could cause the actual results of the Company to differ from the Statements include but not limited to the possibility that the existing and new drug candidates of the Company may not prove safe or effective, the possibility that the existing and new drug candidates of the Company may not receive approval from regulatory agencies in a timely manner or at all, the possibility that the existing and new drug candidates of the Company, if approved, may not be more effective, safer or more cost efficient than the competing drugs, the possibility that the price and other competitive pressures may make the marketing and sale of the drugs of the Company not commercially feasible, the possibility that the efforts of the Company to acquire or in-license and develop additional drug candidates may fail, the Company’s lack of sustained revenue history, the Company’s limited experience in establishing strategic alliances, the Company’s limited marketing experience, the Company’s customer concentration, the possibility of fluctuations in customer orders, evolving market dynamics, the Company’s dependence on third parties for clinical trials, manufacturing, distribution, information and quality control and other risks that are described in further detail in the Company's reports filed with the Taipei Exchange. We do not plan to update any such forward-looking information in the Statements and expressly disclaim any duty and liability to update the information contained in this release except as required by law.